✦ LIBER ✦

Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience

✍ Scribed by Lorenzo Livi, Pierluigi Bonomo, Icro Meattini, Gabriele Simontacchi, Daniela Greto, Isacco Desideri, Fiammetta Meacci, Vieri Scotti, Sara Cecchini, Jacopo Nori, Luis Jose Sanchez, Lorenzo Orzalesi, Fabiola Paiar, Gianpaolo Biti

Book ID: 118821804
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 170 KB
Volume: 30
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-012-0434-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab in combination with paclitax

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation

✍ Konstantin J. Dedes; Klazien Matter-Walstra; Matthias Schwenkglenks; Bernhard C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 718 KB

Adding bevacizumab to paclitaxel in the

Adding bevacizumab to paclitaxel in the first-line treatment of metastatic breast cancer

✍ Kevin R. Fox 📂 Article 📅 2008 🏛 Current Science Inc. 🌐 English ⚖ 186 KB

Maintenance bevacizumab beyond first-lin

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

✍ Alessandra Fabi, Michelangelo Russillo, Gianluigi Ferretti, Giulio Metro, Cecili 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 188 KB

Bevacizumab based chemotherapy in first

Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study

✍ Lamiaa Boulaamane; Saber Boutayeb; Hassan Errihani 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 210 KB

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB

Nanoparticle albumin-bound paclitaxel in

Nanoparticle albumin-bound paclitaxel in 3 dosing schedules with bevacizumab as first line therapy for HER2-negative metastatic breast cancer: an interim safety analysis

✍ A.D. Seidman; A.K. Conlin; M.E. Moynahan; A. Bach; T. Troso-Sandoval; S. Sugarma 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 63 KB